Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares some findings from a study evaluating the use of panobinostat plus ruxolitinib in patients with myelofibrosis (MF) and comments on the growing role of combination therapies in the field. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.